id	sid	tid	token	lemma	pos
cord-274750-fynxciwg	1	1	key	key	JJ
cord-274750-fynxciwg	1	2	:	:	:
cord-274750-fynxciwg	1	3	cord-274750-fynxciwg	cord-274750-fynxciwg	NNP
cord-274750-fynxciwg	2	1	authors	author	NNS
cord-274750-fynxciwg	2	2	:	:	:
cord-274750-fynxciwg	2	3	Peterson	Peterson	NNP
cord-274750-fynxciwg	2	4	,	,	,
cord-274750-fynxciwg	2	5	Danielle	Danielle	NNP
cord-274750-fynxciwg	2	6	;	;	:
cord-274750-fynxciwg	2	7	Damsky	Damsky	NNP
cord-274750-fynxciwg	2	8	,	,	,
cord-274750-fynxciwg	2	9	William	William	NNP
cord-274750-fynxciwg	2	10	;	;	:
cord-274750-fynxciwg	2	11	King	King	NNP
cord-274750-fynxciwg	2	12	,	,	,
cord-274750-fynxciwg	2	13	Brett	Brett	NNP
cord-274750-fynxciwg	2	14	title	title	NN
cord-274750-fynxciwg	2	15	:	:	:
cord-274750-fynxciwg	3	1	Calm	calm	JJ
cord-274750-fynxciwg	3	2	before	before	IN
cord-274750-fynxciwg	3	3	the	the	DT
cord-274750-fynxciwg	3	4	storm	storm	NN
cord-274750-fynxciwg	3	5	:	:	:
cord-274750-fynxciwg	3	6	understanding	understand	VBG
cord-274750-fynxciwg	3	7	the	the	DT
cord-274750-fynxciwg	3	8	role	role	NN
cord-274750-fynxciwg	3	9	of	of	IN
cord-274750-fynxciwg	3	10	JAK	JAK	NNP
cord-274750-fynxciwg	3	11	inhibitors	inhibitor	NNS
cord-274750-fynxciwg	3	12	in	in	IN
cord-274750-fynxciwg	3	13	COVID-19	covid-19	CD
cord-274750-fynxciwg	3	14	date	date	NN
cord-274750-fynxciwg	4	1	:	:	:
cord-274750-fynxciwg	4	2	2020	2020	CD
cord-274750-fynxciwg	4	3	-	-	HYPH
cord-274750-fynxciwg	4	4	04	04	CD
cord-274750-fynxciwg	4	5	-	-	SYM
cord-274750-fynxciwg	4	6	25	25	CD
cord-274750-fynxciwg	4	7	journal	journal	NN
cord-274750-fynxciwg	4	8	:	:	:
cord-274750-fynxciwg	5	1	J	J	NNP
cord-274750-fynxciwg	5	2	Am	be	VBP
cord-274750-fynxciwg	6	1	Acad	Acad	NNP
cord-274750-fynxciwg	6	2	Dermatol	Dermatol	NNP
cord-274750-fynxciwg	7	1	DOI	DOI	NNP
cord-274750-fynxciwg	7	2	:	:	:
cord-274750-fynxciwg	8	1	10.1016	10.1016	CD
cord-274750-fynxciwg	8	2	/	/	SYM
cord-274750-fynxciwg	8	3	j.jaad.2020.04.097	j.jaad.2020.04.097	NN
cord-274750-fynxciwg	8	4	sha	sha	NN
cord-274750-fynxciwg	8	5	:	:	:
cord-274750-fynxciwg	8	6	7bea0dd1b3112fbe7be23439955f7d0c5271b451	7bea0dd1b3112fbe7be23439955f7d0c5271b451	CD
cord-274750-fynxciwg	8	7	doc_id	doc_id	CD
cord-274750-fynxciwg	8	8	:	:	:
cord-274750-fynxciwg	8	9	274750	274750	CD
cord-274750-fynxciwg	8	10	cord_uid	cord_uid	NNS
cord-274750-fynxciwg	8	11	:	:	:
cord-274750-fynxciwg	9	1	fynxciwg	fynxciwg	NNP
cord-274750-fynxciwg	9	2	nan	nan	NNP
cord-274750-fynxciwg	9	3	inhibit	inhibit	VBP
cord-274750-fynxciwg	9	4	proteins	protein	NNS
cord-274750-fynxciwg	9	5	potentially	potentially	RB
cord-274750-fynxciwg	9	6	involved	involve	VBN
cord-274750-fynxciwg	9	7	in	in	IN
cord-274750-fynxciwg	9	8	SARS	SARS	NNP
cord-274750-fynxciwg	9	9	-	-	HYPH
cord-274750-fynxciwg	9	10	CoV-2	CoV-2	NNP
cord-274750-fynxciwg	9	11	entry	entry	NN
cord-274750-fynxciwg	9	12	into	into	IN
cord-274750-fynxciwg	9	13	cells	cell	NNS
cord-274750-fynxciwg	9	14	.	.	.
cord-274750-fynxciwg	10	1	1	1	LS
cord-274750-fynxciwg	11	1	Not	not	RB
cord-274750-fynxciwg	11	2	only	only	RB
cord-274750-fynxciwg	11	3	is	be	VBZ
cord-274750-fynxciwg	11	4	that	that	IN
cord-274750-fynxciwg	11	5	work	work	NN
cord-274750-fynxciwg	11	6	theoretical	theoretical	JJ
cord-274750-fynxciwg	11	7	,	,	,
cord-274750-fynxciwg	11	8	46	46	CD
cord-274750-fynxciwg	11	9	that	that	IN
cord-274750-fynxciwg	11	10	this	this	DT
cord-274750-fynxciwg	11	11	potential	potential	JJ
cord-274750-fynxciwg	11	12	inhibition	inhibition	NN
cord-274750-fynxciwg	11	13	might	may	MD
cord-274750-fynxciwg	11	14	provide	provide	VB
cord-274750-fynxciwg	11	15	clinical	clinical	JJ
cord-274750-fynxciwg	11	16	benefit	benefit	NN
cord-274750-fynxciwg	11	17	to	to	IN
cord-274750-fynxciwg	11	18	patients	patient	NNS
cord-274750-fynxciwg	11	19	infected	infect	VBN
cord-274750-fynxciwg	11	20	with	with	IN
cord-274750-fynxciwg	11	21	SARS	SARS	NNP
cord-274750-fynxciwg	11	22	-	-	HYPH
cord-274750-fynxciwg	11	23	CoV-2	CoV-2	NNP
cord-274750-fynxciwg	11	24	is	be	VBZ
cord-274750-fynxciwg	11	25	even	even	RB
cord-274750-fynxciwg	11	26	47	47	CD
cord-274750-fynxciwg	11	27	further	further	JJ
cord-274750-fynxciwg	11	28	unknown	unknown	JJ
cord-274750-fynxciwg	11	29	.	.	.
cord-274750-fynxciwg	12	1	Also	also	RB
cord-274750-fynxciwg	12	2	,	,	,
cord-274750-fynxciwg	12	3	based	base	VBN
cord-274750-fynxciwg	12	4	on	on	IN
cord-274750-fynxciwg	12	5	in	in	IN
cord-274750-fynxciwg	12	6	vitro	vitro	FW
cord-274750-fynxciwg	12	7	assays	assay	NNS
cord-274750-fynxciwg	12	8	,	,	,
cord-274750-fynxciwg	12	9	the	the	DT
cord-274750-fynxciwg	12	10	concentration	concentration	NN
cord-274750-fynxciwg	12	11	of	of	IN
cord-274750-fynxciwg	12	12	baricitinib	baricitinib	NNP
cord-274750-fynxciwg	12	13	needed	need	VBD
cord-274750-fynxciwg	12	14	to	to	TO
cord-274750-fynxciwg	12	15	inhibit	inhibit	VB
cord-274750-fynxciwg	12	16	48	48	CD
cord-274750-fynxciwg	12	17	AAK1	aak1	JJ
cord-274750-fynxciwg	12	18	and	and	CC
cord-274750-fynxciwg	12	19	clathrin	clathrin	NN
cord-274750-fynxciwg	12	20	-	-	HYPH
cord-274750-fynxciwg	12	21	mediated	mediate	VBN
cord-274750-fynxciwg	12	22	endocytosis	endocytosis	NN
cord-274750-fynxciwg	12	23	would	would	MD
cord-274750-fynxciwg	12	24	likely	likely	RB
cord-274750-fynxciwg	12	25	require	require	VB
cord-274750-fynxciwg	12	26	doses	dose	NNS
cord-274750-fynxciwg	12	27	far	far	RB
cord-274750-fynxciwg	12	28	above	above	IN
cord-274750-fynxciwg	12	29	the	the	DT
cord-274750-fynxciwg	12	30	FDA	FDA	NNP
cord-274750-fynxciwg	12	31	approved	approve	VBD
cord-274750-fynxciwg	12	32	dose	dose	NN
cord-274750-fynxciwg	12	33	49	49	CD
cord-274750-fynxciwg	12	34	of	of	IN
cord-274750-fynxciwg	12	35	baricitinib	baricitinib	NNP
cord-274750-fynxciwg	12	36	2	2	CD
cord-274750-fynxciwg	12	37	mg	mg	NNP
cord-274750-fynxciwg	12	38	daily	daily	RB
cord-274750-fynxciwg	12	39	.	.	.
cord-274750-fynxciwg	13	1	2	2	LS
cord-274750-fynxciwg	14	1	Lastly	lastly	RB
cord-274750-fynxciwg	14	2	,	,	,
cord-274750-fynxciwg	14	3	the	the	DT
cord-274750-fynxciwg	14	4	theoretical	theoretical	JJ
cord-274750-fynxciwg	14	5	effect	effect	NN
cord-274750-fynxciwg	14	6	against	against	IN
cord-274750-fynxciwg	14	7	viral	viral	JJ
cord-274750-fynxciwg	14	8	endocytosis	endocytosis	NN
cord-274750-fynxciwg	14	9	only	only	RB
cord-274750-fynxciwg	14	10	applies	apply	VBZ
cord-274750-fynxciwg	14	11	to	to	IN
cord-274750-fynxciwg	14	12	50	50	CD
cord-274750-fynxciwg	14	13	baricitinib	baricitinib	NN
cord-274750-fynxciwg	14	14	;	;	:
cord-274750-fynxciwg	14	15	this	this	DT
cord-274750-fynxciwg	14	16	is	be	VBZ
cord-274750-fynxciwg	14	17	not	not	RB
cord-274750-fynxciwg	14	18	a	a	DT
cord-274750-fynxciwg	14	19	known	know	VBN
cord-274750-fynxciwg	14	20	property	property	NN
cord-274750-fynxciwg	14	21	of	of	IN
cord-274750-fynxciwg	14	22	other	other	JJ
cord-274750-fynxciwg	14	23	JAK	JAK	NNP
cord-274750-fynxciwg	14	24	inhibitors	inhibitor	NNS
cord-274750-fynxciwg	14	25	,	,	,
cord-274750-fynxciwg	14	26	including	include	VBG
cord-274750-fynxciwg	14	27	upadacitinib	upadacitinib	NN
cord-274750-fynxciwg	14	28	.	.	.
cord-274750-fynxciwg	15	1	Based	base	VBN
cord-274750-fynxciwg	15	2	on	on	IN
cord-274750-fynxciwg	15	3	these	these	DT
cord-274750-fynxciwg	15	4	51	51	CD
cord-274750-fynxciwg	15	5	considerations	consideration	NNS
cord-274750-fynxciwg	15	6	,	,	,
cord-274750-fynxciwg	15	7	we	-PRON-	PRP
cord-274750-fynxciwg	15	8	believe	believe	VBP
cord-274750-fynxciwg	15	9	there	there	EX
cord-274750-fynxciwg	15	10	is	be	VBZ
cord-274750-fynxciwg	15	11	insufficient	insufficient	JJ
cord-274750-fynxciwg	15	12	evidence	evidence	NN
cord-274750-fynxciwg	15	13	to	to	TO
cord-274750-fynxciwg	15	14	recommend	recommend	VB
cord-274750-fynxciwg	15	15	continuing	continue	VBG
cord-274750-fynxciwg	15	16	JAK	JAK	NNP
cord-274750-fynxciwg	15	17	inhibitors	inhibitor	NNS
cord-274750-fynxciwg	15	18	in	in	IN
cord-274750-fynxciwg	15	19	52	52	CD
cord-274750-fynxciwg	15	20	patients	patient	NNS
cord-274750-fynxciwg	15	21	who	who	WP
cord-274750-fynxciwg	15	22	are	be	VBP
cord-274750-fynxciwg	15	23	acutely	acutely	RB
cord-274750-fynxciwg	15	24	infected	infect	VBN
cord-274750-fynxciwg	15	25	with	with	IN
cord-274750-fynxciwg	15	26	SARS	SARS	NNP
cord-274750-fynxciwg	15	27	-	-	HYPH
cord-274750-fynxciwg	15	28	CoV-2	CoV-2	NNP
cord-274750-fynxciwg	15	29	.	.	.
cord-274750-fynxciwg	16	1	53	53	CD
cord-274750-fynxciwg	16	2	54	54	CD
cord-274750-fynxciwg	17	1	Napolitano	Napolitano	NNP
cord-274750-fynxciwg	17	2	et	et	NNP
cord-274750-fynxciwg	17	3	al	al	NNP
cord-274750-fynxciwg	17	4	suggest	suggest	VBP
cord-274750-fynxciwg	17	5	that	that	IN
cord-274750-fynxciwg	17	6	baricitinib	baricitinib	NN
cord-274750-fynxciwg	17	7	and	and	CC
cord-274750-fynxciwg	17	8	upadacitinib	upadacitinib	NN
cord-274750-fynxciwg	17	9	might	may	MD
cord-274750-fynxciwg	17	10	be	be	VB
cord-274750-fynxciwg	17	11	useful	useful	JJ
cord-274750-fynxciwg	17	12	in	in	IN
cord-274750-fynxciwg	17	13	treating	treat	VBG
cord-274750-fynxciwg	17	14	the	the	DT
cord-274750-fynxciwg	17	15	cytokine	cytokine	NN
cord-274750-fynxciwg	17	16	55	55	CD
cord-274750-fynxciwg	17	17	release	release	NN
cord-274750-fynxciwg	17	18	syndrome	syndrome	NN
cord-274750-fynxciwg	17	19	(	(	-LRB-
cord-274750-fynxciwg	17	20	CRS	CRS	NNP
cord-274750-fynxciwg	17	21	)	)	-RRB-
cord-274750-fynxciwg	17	22	that	that	WDT
cord-274750-fynxciwg	17	23	can	can	MD
cord-274750-fynxciwg	17	24	occur	occur	VB
cord-274750-fynxciwg	17	25	in	in	IN
cord-274750-fynxciwg	17	26	SARS	SARS	NNP
cord-274750-fynxciwg	17	27	-	-	HYPH
cord-274750-fynxciwg	17	28	CoV-2	CoV-2	NNP
cord-274750-fynxciwg	17	29	infection	infection	NN
cord-274750-fynxciwg	17	30	.	.	.
cord-274750-fynxciwg	18	1	We	-PRON-	PRP
cord-274750-fynxciwg	18	2	strongly	strongly	RB
cord-274750-fynxciwg	18	3	agree	agree	VBP
cord-274750-fynxciwg	18	4	that	that	IN
cord-274750-fynxciwg	18	5	there	there	EX
cord-274750-fynxciwg	18	6	may	may	MD
cord-274750-fynxciwg	18	7	be	be	VB
cord-274750-fynxciwg	18	8	a	a	DT
cord-274750-fynxciwg	18	9	56	56	CD
cord-274750-fynxciwg	18	10	role	role	NN
cord-274750-fynxciwg	18	11	for	for	IN
cord-274750-fynxciwg	18	12	JAK	JAK	NNP
cord-274750-fynxciwg	18	13	inhibitors	inhibitor	NNS
cord-274750-fynxciwg	18	14	in	in	IN
cord-274750-fynxciwg	18	15	treating	treat	VBG
cord-274750-fynxciwg	18	16	SARS	SARS	NNP
cord-274750-fynxciwg	18	17	-	-	HYPH
cord-274750-fynxciwg	18	18	CoV-2-associated	cov-2-associate	VBN
cord-274750-fynxciwg	18	19	CRS	CRS	NNP
cord-274750-fynxciwg	18	20	.	.	.
cord-274750-fynxciwg	19	1	However	however	RB
cord-274750-fynxciwg	19	2	,	,	,
cord-274750-fynxciwg	19	3	it	-PRON-	PRP
cord-274750-fynxciwg	19	4	is	be	VBZ
cord-274750-fynxciwg	19	5	important	important	JJ
cord-274750-fynxciwg	19	6	to	to	TO
cord-274750-fynxciwg	19	7	note	note	VB
cord-274750-fynxciwg	19	8	that	that	IN
cord-274750-fynxciwg	19	9	this	this	DT
cord-274750-fynxciwg	19	10	57	57	CD
cord-274750-fynxciwg	19	11	is	be	VBZ
cord-274750-fynxciwg	19	12	typically	typically	RB
cord-274750-fynxciwg	19	13	a	a	DT
cord-274750-fynxciwg	19	14	late	late	JJ
cord-274750-fynxciwg	19	15	manifestation	manifestation	NN
cord-274750-fynxciwg	19	16	of	of	IN
cord-274750-fynxciwg	19	17	disease	disease	NN
cord-274750-fynxciwg	19	18	that	that	WDT
cord-274750-fynxciwg	19	19	occurs	occur	VBZ
cord-274750-fynxciwg	19	20	only	only	RB
cord-274750-fynxciwg	19	21	in	in	IN
cord-274750-fynxciwg	19	22	a	a	DT
cord-274750-fynxciwg	19	23	subset	subset	NN
cord-274750-fynxciwg	19	24	of	of	IN
cord-274750-fynxciwg	19	25	patients	patient	NNS
cord-274750-fynxciwg	19	26	.	.	.
cord-274750-fynxciwg	20	1	Furthermore	furthermore	RB
cord-274750-fynxciwg	20	2	,	,	,
cord-274750-fynxciwg	20	3	there	there	EX
cord-274750-fynxciwg	20	4	is	be	VBZ
cord-274750-fynxciwg	20	5	58	58	CD
cord-274750-fynxciwg	20	6	evidence	evidence	NN
cord-274750-fynxciwg	20	7	in	in	IN
cord-274750-fynxciwg	20	8	both	both	DT
cord-274750-fynxciwg	20	9	rhesus	rhesus	NN
cord-274750-fynxciwg	20	10	macaques	macaque	NNS
cord-274750-fynxciwg	20	11	and	and	CC
cord-274750-fynxciwg	20	12	mice	mouse	NNS
cord-274750-fynxciwg	20	13	infected	infect	VBN
cord-274750-fynxciwg	20	14	with	with	IN
cord-274750-fynxciwg	20	15	the	the	DT
cord-274750-fynxciwg	20	16	original	original	JJ
cord-274750-fynxciwg	20	17	SARS	SARS	NNP
cord-274750-fynxciwg	20	18	virus	virus	NN
cord-274750-fynxciwg	20	19	,	,	,
cord-274750-fynxciwg	20	20	SARS	SARS	NNP
cord-274750-fynxciwg	20	21	-	-	HYPH
cord-274750-fynxciwg	20	22	CoV	CoV	NNP
cord-274750-fynxciwg	20	23	,	,	,
cord-274750-fynxciwg	20	24	that	that	IN
cord-274750-fynxciwg	20	25	a	a	DT
cord-274750-fynxciwg	20	26	59	59	CD
cord-274750-fynxciwg	20	27	suboptimal	suboptimal	JJ
cord-274750-fynxciwg	20	28	early	early	JJ
cord-274750-fynxciwg	20	29	anti	anti	JJ
cord-274750-fynxciwg	20	30	-	-	JJ
cord-274750-fynxciwg	20	31	viral	viral	JJ
cord-274750-fynxciwg	20	32	type	type	NN
cord-274750-fynxciwg	20	33	I	-PRON-	PRP
cord-274750-fynxciwg	20	34	interferon	interferon	VBD
cord-274750-fynxciwg	20	35	response	response	NN
cord-274750-fynxciwg	20	36	may	may	MD
cord-274750-fynxciwg	20	37	predispose	predispose	VB
cord-274750-fynxciwg	20	38	to	to	IN
cord-274750-fynxciwg	20	39	this	this	DT
cord-274750-fynxciwg	20	40	late	late	JJ
cord-274750-fynxciwg	20	41	manifestation	manifestation	NN
cord-274750-fynxciwg	20	42	.	.	.
cord-274750-fynxciwg	21	1	3,4	3,4	CD
cord-274750-fynxciwg	21	2	JAK	JAK	NNP
cord-274750-fynxciwg	21	3	60	60	CD
cord-274750-fynxciwg	21	4	cytokines	cytokine	NNS
cord-274750-fynxciwg	21	5	including	include	VBG
cord-274750-fynxciwg	21	6	IL-2	IL-2	NNP
cord-274750-fynxciwg	21	7	,	,	,
cord-274750-fynxciwg	21	8	interferon	interferon	NN
cord-274750-fynxciwg	21	9	gamma	gamma	NN
cord-274750-fynxciwg	21	10	,	,	,
cord-274750-fynxciwg	21	11	GM	GM	NNP
cord-274750-fynxciwg	21	12	-	-	HYPH
cord-274750-fynxciwg	21	13	CSF	CSF	NNP
cord-274750-fynxciwg	21	14	,	,	,
cord-274750-fynxciwg	21	15	and	and	CC
cord-274750-fynxciwg	21	16	G	G	NNP
cord-274750-fynxciwg	21	17	-	-	HYPH
cord-274750-fynxciwg	21	18	CSF	CSF	NNP
cord-274750-fynxciwg	21	19	.	.	.
cord-274750-fynxciwg	22	1	Important	important	JJ
cord-274750-fynxciwg	22	2	to	to	TO
cord-274750-fynxciwg	22	3	note	note	VB
cord-274750-fynxciwg	22	4	is	be	VBZ
cord-274750-fynxciwg	22	5	that	that	IN
cord-274750-fynxciwg	22	6	the	the	DT
cord-274750-fynxciwg	22	7	64	64	CD
cord-274750-fynxciwg	22	8	theoretical	theoretical	JJ
cord-274750-fynxciwg	22	9	benefit	benefit	NN
cord-274750-fynxciwg	22	10	of	of	IN
cord-274750-fynxciwg	22	11	JAK	JAK	NNP
cord-274750-fynxciwg	22	12	inhibitors	inhibitor	NNS
cord-274750-fynxciwg	22	13	in	in	IN
cord-274750-fynxciwg	22	14	this	this	DT
cord-274750-fynxciwg	22	15	setting	setting	NN
cord-274750-fynxciwg	22	16	is	be	VBZ
cord-274750-fynxciwg	22	17	not	not	RB
cord-274750-fynxciwg	22	18	limited	limited	JJ
cord-274750-fynxciwg	22	19	to	to	IN
cord-274750-fynxciwg	22	20	upadacitinib	upadacitinib	NN
cord-274750-fynxciwg	22	21	and	and	CC
cord-274750-fynxciwg	22	22	baricitinib	baricitinib	NN
cord-274750-fynxciwg	22	23	but	but	CC
cord-274750-fynxciwg	22	24	also	also	RB
cord-274750-fynxciwg	22	25	65	65	CD
cord-274750-fynxciwg	22	26	applies	apply	VBZ
cord-274750-fynxciwg	22	27	to	to	IN
cord-274750-fynxciwg	22	28	other	other	JJ
cord-274750-fynxciwg	22	29	JAK	JAK	NNP
cord-274750-fynxciwg	22	30	inhibitors	inhibitor	NNS
cord-274750-fynxciwg	22	31	including	include	VBG
cord-274750-fynxciwg	22	32	ruxolitinib	ruxolitinib	NNP
cord-274750-fynxciwg	22	33	and	and	CC
cord-274750-fynxciwg	22	34	tofacitinib	tofacitinib	NNP
cord-274750-fynxciwg	22	35	.	.	.
cord-274750-fynxciwg	23	1	We	-PRON-	PRP
cord-274750-fynxciwg	23	2	and	and	CC
cord-274750-fynxciwg	23	3	others	other	NNS
cord-274750-fynxciwg	23	4	are	be	VBP
cord-274750-fynxciwg	23	5	undertaking	undertake	VBG
cord-274750-fynxciwg	23	6	66	66	CD
cord-274750-fynxciwg	23	7	clinical	clinical	JJ
cord-274750-fynxciwg	23	8	trials	trial	NNS
cord-274750-fynxciwg	23	9	to	to	TO
cord-274750-fynxciwg	23	10	evaluate	evaluate	VB
cord-274750-fynxciwg	23	11	JAK	JAK	NNP
cord-274750-fynxciwg	23	12	inhibitors	inhibitor	NNS
cord-274750-fynxciwg	23	13	for	for	IN
cord-274750-fynxciwg	23	14	SARS	SARS	NNP
cord-274750-fynxciwg	23	15	-	-	HYPH
cord-274750-fynxciwg	23	16	CoV-2-associated	cov-2-associate	VBN
cord-274750-fynxciwg	23	17	CRS	CRS	NNP
cord-274750-fynxciwg	23	18	,	,	,
cord-274750-fynxciwg	23	19	and	and	CC
cord-274750-fynxciwg	23	20	it	-PRON-	PRP
cord-274750-fynxciwg	23	21	will	will	MD
cord-274750-fynxciwg	23	22	be	be	VB
cord-274750-fynxciwg	23	23	interesting	interesting	JJ
cord-274750-fynxciwg	23	24	to	to	TO
cord-274750-fynxciwg	23	25	see	see	VB
cord-274750-fynxciwg	23	26	67	67	CD
cord-274750-fynxciwg	23	27	what	what	WP
cord-274750-fynxciwg	23	28	they	-PRON-	PRP
cord-274750-fynxciwg	23	29	show	show	VBP
cord-274750-fynxciwg	23	30	.	.	.
cord-274750-fynxciwg	24	1	68	68	CD
cord-274750-fynxciwg	25	1	In	in	IN
cord-274750-fynxciwg	25	2	summary	summary	NN
cord-274750-fynxciwg	25	3	,	,	,
cord-274750-fynxciwg	25	4	we	-PRON-	PRP
cord-274750-fynxciwg	25	5	believe	believe	VBP
cord-274750-fynxciwg	25	6	there	there	EX
cord-274750-fynxciwg	25	7	is	be	VBZ
cord-274750-fynxciwg	25	8	insufficient	insufficient	JJ
cord-274750-fynxciwg	25	9	evidence	evidence	NN
cord-274750-fynxciwg	25	10	to	to	TO
cord-274750-fynxciwg	25	11	recommend	recommend	VB
cord-274750-fynxciwg	25	12	that	that	IN
cord-274750-fynxciwg	25	13	JAK	JAK	NNP
cord-274750-fynxciwg	25	14	inhibitors	inhibitor	NNS
cord-274750-fynxciwg	25	15	be	be	VB
cord-274750-fynxciwg	25	16	continued	continue	VBN
cord-274750-fynxciwg	25	17	in	in	IN
cord-274750-fynxciwg	25	18	70	70	CD
cord-274750-fynxciwg	25	19	all	all	DT
cord-274750-fynxciwg	25	20	patients	patient	NNS
cord-274750-fynxciwg	25	21	taking	take	VBG
cord-274750-fynxciwg	25	22	these	these	DT
cord-274750-fynxciwg	25	23	medications	medication	NNS
cord-274750-fynxciwg	25	24	who	who	WP
cord-274750-fynxciwg	25	25	are	be	VBP
cord-274750-fynxciwg	25	26	acutely	acutely	RB
cord-274750-fynxciwg	25	27	infected	infect	VBN
cord-274750-fynxciwg	25	28	with	with	IN
cord-274750-fynxciwg	25	29	SARS	SARS	NNP
cord-274750-fynxciwg	25	30	-	-	HYPH
cord-274750-fynxciwg	25	31	CoV-2	CoV-2	NNP
cord-274750-fynxciwg	25	32	.	.	.
cord-274750-fynxciwg	26	1	While	while	IN
cord-274750-fynxciwg	26	2	JAK	JAK	NNP
cord-274750-fynxciwg	26	3	inhibitors	inhibitor	NNS
cord-274750-fynxciwg	26	4	71	71	CD
cord-274750-fynxciwg	26	5	may	may	MD
cord-274750-fynxciwg	26	6	prove	prove	VB
cord-274750-fynxciwg	26	7	useful	useful	JJ
cord-274750-fynxciwg	26	8	in	in	IN
cord-274750-fynxciwg	26	9	the	the	DT
cord-274750-fynxciwg	26	10	treatment	treatment	NN
cord-274750-fynxciwg	26	11	of	of	IN
cord-274750-fynxciwg	26	12	SARS	SARS	NNP
cord-274750-fynxciwg	26	13	-	-	HYPH
cord-274750-fynxciwg	26	14	CoV-2-associated	cov-2-associate	VBN
cord-274750-fynxciwg	26	15	CRS	CRS	NNP
cord-274750-fynxciwg	26	16	,	,	,
cord-274750-fynxciwg	26	17	this	this	DT
cord-274750-fynxciwg	26	18	is	be	VBZ
cord-274750-fynxciwg	26	19	a	a	DT
cord-274750-fynxciwg	26	20	separate	separate	JJ
cord-274750-fynxciwg	26	21	consideration	consideration	NN
cord-274750-fynxciwg	26	22	of	of	IN
cord-274750-fynxciwg	26	23	a	a	DT
cord-274750-fynxciwg	26	24	72	72	CD
cord-274750-fynxciwg	26	25	relatively	relatively	RB
cord-274750-fynxciwg	26	26	uncommon	uncommon	JJ
cord-274750-fynxciwg	26	27	manifestation	manifestation	NN
cord-274750-fynxciwg	26	28	of	of	IN
cord-274750-fynxciwg	26	29	this	this	DT
cord-274750-fynxciwg	26	30	viral	viral	JJ
cord-274750-fynxciwg	26	31	infection	infection	NN
cord-274750-fynxciwg	26	32	that	that	WDT
cord-274750-fynxciwg	26	33	occurs	occur	VBZ
cord-274750-fynxciwg	26	34	late	late	RB
cord-274750-fynxciwg	26	35	in	in	IN
cord-274750-fynxciwg	26	36	disease	disease	NN
cord-274750-fynxciwg	26	37	course	course	NN
cord-274750-fynxciwg	26	38	.	.	.
cord-274750-fynxciwg	27	1	73	73	CD
cord-274750-fynxciwg	27	2	74	74	CD
cord-274750-fynxciwg	27	3	75	75	CD
cord-274750-fynxciwg	27	4	76	76	CD
cord-274750-fynxciwg	27	5	Baricitinib	Baricitinib	NNP
cord-274750-fynxciwg	27	6	as	as	IN
cord-274750-fynxciwg	27	7	potential	potential	JJ
cord-274750-fynxciwg	27	8	treatment	treatment	NN
cord-274750-fynxciwg	27	9	for	for	IN
cord-274750-fynxciwg	27	10	2019-nCoV	2019-ncov	CD
cord-274750-fynxciwg	27	11	acute	acute	JJ
cord-274750-fynxciwg	27	12	78	78	CD
cord-274750-fynxciwg	27	13	respiratory	respiratory	JJ
cord-274750-fynxciwg	27	14	disease	disease	NN
cord-274750-fynxciwg	27	15	COVID-19	covid-19	NN
cord-274750-fynxciwg	27	16	:	:	:
cord-274750-fynxciwg	27	17	combining	combine	VBG
cord-274750-fynxciwg	27	18	antiviral	antiviral	JJ
cord-274750-fynxciwg	27	19	and	and	CC
cord-274750-fynxciwg	27	20	anti	anti	JJ
cord-274750-fynxciwg	27	21	-	-	JJ
cord-274750-fynxciwg	27	22	inflammatory	inflammatory	JJ
cord-274750-fynxciwg	27	23	80	80	CD
cord-274750-fynxciwg	27	24	treatments	treatment	NNS
cord-274750-fynxciwg	28	1	Dysregulated	Dysregulated	NNP
cord-274750-fynxciwg	28	2	Type	Type	NNP
cord-274750-fynxciwg	29	1	I	-PRON-	PRP
cord-274750-fynxciwg	30	1	Interferon	interferon	NN
cord-274750-fynxciwg	30	2	and	and	CC
cord-274750-fynxciwg	30	3	Inflammatory	Inflammatory	NNP
cord-274750-fynxciwg	30	4	82	82	CD
cord-274750-fynxciwg	30	5	Responses	response	NNS
cord-274750-fynxciwg	30	6	Cause	cause	VBP
cord-274750-fynxciwg	30	7	Lethal	lethal	JJ
cord-274750-fynxciwg	30	8	Pneumonia	pneumonia	NN
cord-274750-fynxciwg	30	9	in	in	IN
cord-274750-fynxciwg	31	1	SARS	SARS	NNP
cord-274750-fynxciwg	31	2	-	-	HYPH
cord-274750-fynxciwg	31	3	CoV	CoV	NNP
cord-274750-fynxciwg	31	4	-	-	HYPH
cord-274750-fynxciwg	31	5	Infected	infected	JJ
cord-274750-fynxciwg	31	6	Mice	Mice	NNP
cord-274750-fynxciwg	31	7	Microbe	microbe	NN
cord-274750-fynxciwg	31	8	Exacerbated	exacerbate	VBN
cord-274750-fynxciwg	32	1	Innate	Innate	NNP
cord-274750-fynxciwg	32	2	Host	Host	NNP
cord-274750-fynxciwg	32	3	Response	Response	NNP
cord-274750-fynxciwg	32	4	to	to	IN
cord-274750-fynxciwg	32	5	SARS	SARS	NNP
cord-274750-fynxciwg	32	6	-	-	HYPH
cord-274750-fynxciwg	32	7	CoV	CoV	NNP
cord-274750-fynxciwg	32	8	in	in	IN
cord-274750-fynxciwg	32	9	85	85	CD
cord-274750-fynxciwg	32	10	Aged	aged	JJ
cord-274750-fynxciwg	32	11	Non	Non	NNP
cord-274750-fynxciwg	32	12	-	-	JJ
cord-274750-fynxciwg	32	13	Human	human	JJ
cord-274750-fynxciwg	32	14	Primates	Primates	NNPS
cord-274750-fynxciwg	32	15	.	.	.
cord-274750-fynxciwg	33	1	Baric	Baric	NNP
cord-274750-fynxciwg	33	2	RS	rs	NN